252 related articles for article (PubMed ID: 38243252)
1. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses.
Kamrani A; Nasiri H; Hassanzadeh A; Ahmadian Heris J; Mohammadinasab R; Sadeghvand S; Sadeghi M; Valedkarimi Z; Hosseinzadeh R; Shomali N; Akbari M
Cell Commun Signal; 2024 Jan; 22(1):56. PubMed ID: 38243252
[TBL] [Abstract][Full Text] [Related]
2. New immunotherapeutic approaches for cancer treatment.
Kamrani A; Hosseinzadeh R; Shomali N; Heris JA; Shahabi P; Mohammadinasab R; Sadeghvand S; Ghahremanzadeh K; Sadeghi M; Akbari M
Pathol Res Pract; 2023 Aug; 248():154632. PubMed ID: 37480597
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.
Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A
Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
7. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
Heidbuechel JPW; Engeland CE
J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
[TBL] [Abstract][Full Text] [Related]
10. T-cell-based immunotherapy in colorectal cancer.
Feng M; Zhao Z; Yang M; Ji J; Zhu D
Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
12. Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses.
Zarezadeh Mehrabadi A; Roozbahani F; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Esmaeili Gouvarchin Ghaleh H
World J Surg Oncol; 2022 Jan; 20(1):16. PubMed ID: 35027068
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with Clinical Insight.
Ray SK; Meshram Y; Mukherjee S
Curr Mol Med; 2021; 21(3):221-236. PubMed ID: 32838717
[TBL] [Abstract][Full Text] [Related]
14. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
[TBL] [Abstract][Full Text] [Related]
15. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
17. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
Crupi MJF; Bell JC; Singaravelu R
Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
[TBL] [Abstract][Full Text] [Related]
18. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
19. A promising future in cancer immunotherapy: Oncolytic viruses.
Seyed-Khorrami SM; Azadi A; Rastegarvand N; Habibian A; Soleimanjahi H; Łos MJ
Eur J Pharmacol; 2023 Dec; 960():176063. PubMed ID: 37797673
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine for advanced cancer immunotherapy.
Diep YN; Kim TJ; Cho H; Lee LP
J Control Release; 2022 Nov; 351():1017-1037. PubMed ID: 36220487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]